Juxtapid (lomitapide) Capsules
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
August 2014
DRUG INTERACTIONS
* re-categorize the combination of tipranavir/ritonavir from the list of weak CYP3A4...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Norvir